518 related articles for article (PubMed ID: 25605410)
1. Deubiquitinases and the new therapeutic opportunities offered to cancer.
Pfoh R; Lacdao IK; Saridakis V
Endocr Relat Cancer; 2015 Feb; 22(1):T35-54. PubMed ID: 25605410
[TBL] [Abstract][Full Text] [Related]
2. Deubiquitinases in cancer.
Wei R; Liu X; Yu W; Yang T; Cai W; Liu J; Huang X; Xu GT; Zhao S; Yang J; Liu S
Oncotarget; 2015 May; 6(15):12872-89. PubMed ID: 25972356
[TBL] [Abstract][Full Text] [Related]
3. Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics.
Lill JR; Wertz IE
Trends Pharmacol Sci; 2014 Apr; 35(4):187-207. PubMed ID: 24717260
[TBL] [Abstract][Full Text] [Related]
4. Could dysregulation of UPS be a common underlying mechanism for cancer and neurodegeneration? Lessons from UCHL1.
Jara JH; Frank DD; Özdinler PH
Cell Biochem Biophys; 2013 Sep; 67(1):45-53. PubMed ID: 23695785
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets.
Shi D; Grossman SR
Cancer Biol Ther; 2010 Oct; 10(8):737-47. PubMed ID: 20930542
[TBL] [Abstract][Full Text] [Related]
6. Deubiquitinases (DUBs) and DUB inhibitors: a patent review.
Farshi P; Deshmukh RR; Nwankwo JO; Arkwright RT; Cvek B; Liu J; Dou QP
Expert Opin Ther Pat; 2015; 25(10):1191-1208. PubMed ID: 26077642
[TBL] [Abstract][Full Text] [Related]
7. Dissenting degradation: Deubiquitinases in cell cycle and cancer.
Bonacci T; Emanuele MJ
Semin Cancer Biol; 2020 Dec; 67(Pt 2):145-158. PubMed ID: 32201366
[TBL] [Abstract][Full Text] [Related]
8. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer.
Pal A; Young MA; Donato NJ
Cancer Res; 2014 Sep; 74(18):4955-66. PubMed ID: 25172841
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinase inhibition as a cancer therapeutic strategy.
D'Arcy P; Wang X; Linder S
Pharmacol Ther; 2015 Mar; 147():32-54. PubMed ID: 25444757
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells.
Zhang K; Sun T; Li W; Guo Y; Li A; Hsieh M; Wang J; Wu J; Arvanitis L; Raz DJ
Cell Commun Signal; 2023 Nov; 21(1):319. PubMed ID: 37946202
[TBL] [Abstract][Full Text] [Related]
11. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Crosas B
Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
[TBL] [Abstract][Full Text] [Related]
12. Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors.
Chen S; Liu Y; Zhou H
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925279
[TBL] [Abstract][Full Text] [Related]
13. Emerging roles of deubiquitinases in cancer-associated pathways.
Sacco JJ; Coulson JM; Clague MJ; Urbé S
IUBMB Life; 2010 Feb; 62(2):140-57. PubMed ID: 20073038
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ubiquitin pathway for cancer treatment.
Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: translational potential of deubiquitinases as drug targets.
D'Arcy P; Linder S
Clin Cancer Res; 2014 Aug; 20(15):3908-14. PubMed ID: 25085788
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitination regulates the neuroprotective function of the deubiquitinase ataxin-3 in vivo.
Tsou WL; Burr AA; Ouyang M; Blount JR; Scaglione KM; Todi SV
J Biol Chem; 2013 Nov; 288(48):34460-9. PubMed ID: 24106274
[TBL] [Abstract][Full Text] [Related]
17. The role of ubiquitin-specific peptidases in glioma progression.
Liang W; Fang J; Zhou S; Hu W; Yang Z; Li Z; Dai L; Tao Y; Fu X; Wang X
Biomed Pharmacother; 2022 Feb; 146():112585. PubMed ID: 34968923
[TBL] [Abstract][Full Text] [Related]
18. The role of ubiquitin-specific peptidases in cancer progression.
Young MJ; Hsu KC; Lin TE; Chang WC; Hung JJ
J Biomed Sci; 2019 May; 26(1):42. PubMed ID: 31133011
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications.
Fang Y; Shen X
Cancer Metastasis Rev; 2017 Dec; 36(4):669-682. PubMed ID: 29080080
[TBL] [Abstract][Full Text] [Related]
20. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry.
Ritorto MS; Ewan R; Perez-Oliva AB; Knebel A; Buhrlage SJ; Wightman M; Kelly SM; Wood NT; Virdee S; Gray NS; Morrice NA; Alessi DR; Trost M
Nat Commun; 2014 Aug; 5():4763. PubMed ID: 25159004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
